Avidity Biosciences (RNAM) Spins Off Atrium Therapeutics (RNA): What Investors Need to Know

Avidity Biosciences (RNAM) completed the spin-off of Atrium Therapeutics (RNA) on February 26, 2026, just one day before Novartis closed its $72.00 per share acquisition of Avidity in a deal valued at roughly $12 billion. Atrium is now trading independently on the Nasdaq Global Select Market under the ticker RNA — inheriting Avidity’s former symbol — while Avidity trades temporarily under RNAM ahead of its delisting following the merger.

The separation created a new publicly traded biotech focused entirely on precision cardiology, armed with $270 million in cash and Avidity’s RNA delivery platform adapted for heart tissue. At $14.79 per share, Atrium represents an interesting early-stage biotech play — but one with significant clinical risk attached.

The Separation

This spinoff wasn’t born out of antitrust concerns. When Novartis announced the Avidity acquisition in October 2025, CEO Vas Narasimhan said the spin-off was simply the most straightforward way to handle Avidity’s early-stage cardiology assets and existing collaboration agreements with Bristol-Myers Squibb and Eli Lilly. Novartis wanted Avidity’s late-stage neuromuscular pipeline — specifically del-desiran, del-brax, and del-zota, three programs targeting rare neuromuscular diseases — not the early-stage heart programs.

The structure also delivered a tax advantage. By separating the cardiology assets before the merger rather than having Avidity sell them directly, the parties avoided subjecting Novartis’s $72/share payment to corporate-level income tax that would have applied on a direct asset sale. That translates to more after-tax value for Avidity shareholders.

Avidity contributed approximately $270 million in cash to Atrium before the distribution, with Novartis guaranteeing payment of any shortfall. This gives Atrium a meaningful runway for a preclinical-stage company, though burning through it is inevitable given the capital requirements of clinical development.

Why This Is Interesting

Atrium is essentially a bet on whether Avidity’s antibody oligonucleotide conjugate (AOC) platform can be extended from skeletal muscle to cardiac tissue. Avidity proved the platform works for targeted RNA delivery to muscle — that was the basis of the Novartis acquisition. Atrium inherits next-generation versions of that technology specifically engineered for the heart.

The company’s two lead programs target rare genetic cardiomyopathies with no approved treatments: ATR-1072 for PRKAG2 syndrome (IND filing expected in the second half of 2026) and ATR-1086 for phospholamban cardiomyopathy (IND targeted for 2027). Two additional undisclosed research-stage targets round out the early pipeline. These are small patient populations, but the unmet need is severe and the regulatory path for rare diseases can be accelerated.

The inherited collaborations with Bristol-Myers Squibb and Eli Lilly add optionality. While specific terms of those deals haven’t been fully disclosed, having two major pharma partners validating the platform’s cardiovascular potential is a meaningful signal for a preclinical company. The right of first negotiation (ROFN) that one collaboration partner held on certain assets expired on February 5, 2026 without a deal, meaning Atrium retains full control of those assets.

Key Terms

• Distribution ratio: 1 share of Atrium (RNA) for every 10 shares of Avidity (RNAM) held on the record date of February 12, 2026
• Cash contribution: Approximately $270 million funded to Atrium by Avidity prior to distribution, with Novartis guaranteeing any shortfall
• Fractional shares: Cash in lieu — fractional shares are aggregated, sold on the open market, and proceeds distributed to shareholders
• Ticker transition: Atrium trades under RNA on Nasdaq (Avidity’s former symbol). Avidity temporarily traded as RNAM before delisting post-merger

License Agreement Highlights

The amended and restated license agreement between Atrium and Avidity (now a Novartis subsidiary) is the key document defining the ongoing relationship:

• Novartis gets an exclusive, royalty-free, perpetual, irrevocable license to Atrium’s platform technology (the SpinCo Platform) for all non-cardiovascular products worldwide. This is the license that lets Novartis continue developing the neuromuscular pipeline without depending on Atrium.
• Novartis also gets a non-exclusive, royalty-free license for cardiovascular products, meaning both companies can develop heart-focused therapies using the platform.
• Atrium gets an exclusive, royalty-free license back from Novartis for its assigned technology and RemainCo intellectual property to develop certain excluded products.
• Platform technology assignment: Atrium’s platform technology ultimately transfers to Novartis upon certain trigger events (including change of control of Atrium), though Atrium retains the right to use it for cardiovascular applications.
• Right of first negotiation: The agreement includes ROFN provisions for certain prospective transactions, giving the parties a structured process for future collaboration or licensing deals.
• Territory: Worldwide for all licenses.
• Manufacturing technology transfer: Atrium will provide manufacturing know-how and technology transfer support to Novartis for existing compounds.

The critical takeaway: these licenses are royalty-free and perpetual. There are no ongoing milestone payments or royalty streams flowing between the companies. The value to Atrium lies in retaining the exclusive right to develop cardiovascular applications of the platform, not in any licensing revenue from Novartis.

Tax Treatment

This is not a tax-free spinoff. The distribution is treated as a taxable dividend to the extent of Avidity’s current or accumulated earnings and profits. Avidity has not calculated its earnings and profits under federal tax principles, so shareholders should expect to treat the full fair market value of the Atrium shares received as dividend income. Non-U.S. holders face potential withholding at applicable rates, which may be satisfied by the withholding agent selling a portion of the Atrium shares that would otherwise be distributed. The parties elected Section 336(e) treatment, giving Atrium a stepped-up fair market value tax basis in its assets.

Timeline

Risks

• Preclinical-stage pipeline. Both lead programs are preclinical. Atrium has zero clinical data in cardiac tissue, and the leap from skeletal muscle delivery (where Avidity proved the platform) to cardiac delivery is scientifically non-trivial. There is no guarantee the AOC platform will work in the heart.
• Cash runway versus burn rate. $270 million sounds substantial, but preclinical-to-Phase 1 development is expensive. If both programs advance on schedule, Atrium will likely need to raise additional capital within 2-3 years, potentially diluting shareholders.
• Taxable distribution impact. Shareholders who received Atrium shares in the distribution face an immediate tax liability on the fair market value of those shares, treated as dividend income. Some investors may sell to cover the tax bill, creating near-term selling pressure.
• Platform technology assignment risk. Under the license agreement, Atrium’s platform technology eventually gets assigned to Novartis. While Atrium retains cardiovascular rights, this limits the long-term strategic value of the IP Atrium holds.
• No revenue, no approved products. Atrium is a pure-play development-stage biotech. Revenue depends entirely on advancing programs to approval — a process that will take many years even under optimistic scenarios.
• Small patient populations. PRKAG2 syndrome and PLN cardiomyopathy are ultra-rare conditions. Even with approval, commercial revenues may be modest unless the platform expands into broader cardiology indications.
• Key person and operational risk. Atrium has never operated as a standalone company. Building out independent operations while advancing two preclinical programs simultaneously is a significant execution challenge.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.